Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b, Open-label, Dose-escalation and Dose-expansion, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of MX006 in Patients With Selected Advanced Solid Tumor Types Known to Express B7-H3

NCT07807241 is registered in ClinicalTrials.gov with Myricx Pharma Limited as lead sponsor.

NCT NCT07807241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b, Open-label, Dose-escalation and Dose-expansion, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of MX006 in Patients With Selected Advanced Solid Tumor Types Known to Express B7-H3
Lead sponsor
Myricx Pharma Limited
Phase
Phase 1
Overall status
Recruiting
Start date
July 20, 2026
Completion date
July 31, 2030
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumors known to express b7-h3